Atyr Pharma Inc (NASDAQ: ATYR)’s stock price has surge by 4.11relation to previous closing price of 4.75. Nevertheless, the company has seen a 27.78% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-20 that SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
Is It Worth Investing in Atyr Pharma Inc (NASDAQ: ATYR) Right Now?
Company’s 36-month beta value is 0.87.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATYR is 86.06M, and currently, short sellers hold a 14.74% ratio of that floaft. The average trading volume of ATYR on June 03, 2025 was 1.50M shares.
ATYR’s Market Performance
ATYR stock saw an increase of 27.78% in the past week, with a monthly gain of 37.36% and a quarterly increase of 63.20%. The volatility ratio for the week is 2.88%, and the volatility levels for the last 30 days are 5.07% for Atyr Pharma Inc (ATYR). The simple moving average for the past 20 days is 34.41% for ATYR’s stock, with a 59.40% simple moving average for the past 200 days.
Analysts’ Opinion of ATYR
Many brokerage firms have already submitted their reports for ATYR stocks, with Leerink Partners repeating the rating for ATYR by listing it as a “Outperform.” The predicted price for ATYR in the upcoming period, according to Leerink Partners is $16 based on the research report published on February 18, 2025 of the current year 2025.
Wells Fargo gave a rating of “Overweight” to ATYR, setting the target price at $17 in the report published on October 04th of the previous year.
ATYR Trading at 46.61% from the 50-Day Moving Average
After a stumble in the market that brought ATYR to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 2.38% of gains for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATYR starting from Gross Jane A, who purchase 3,750 shares at the price of $4.00 back on Mar 17 ’25. After this action, Gross Jane A now owns 9,750 shares of Atyr Pharma Inc, valued at $15,000 using the latest closing price.
Broadfoot Jill Marie, the Chief Financial Officer of Atyr Pharma Inc, sale 1,254 shares at $3.78 during a trade that took place back on Feb 04 ’25, which means that Broadfoot Jill Marie is holding 31,763 shares at $4,740 based on the most recent closing price.
Stock Fundamentals for ATYR
The total capital return value is set at -0.77. Equity return is now at value -79.51, with -60.25 for asset returns.
Based on Atyr Pharma Inc (ATYR), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -4.79.
Currently, EBITDA for the company is -66.37 million with net debt to EBITDA at -0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.79.
Conclusion
In a nutshell, Atyr Pharma Inc (ATYR) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
